Global B2B Pharmaceutical Sourcing · Dossier Licensing · Named-Patient Access
💬 WhatsApp · Sign in · Register
Sarilumab bulk supplier for pharma manufacturers

Sarilumab Suppliers & Bulk Manufacturers

Available Forms: injection (prefilled syringe)

Available Strengths: 150 mg/1.14 mL, 200 mg/1.14 mL

Reference Brands: Kevzara (USA/EU)

Category: Immune Disorder

Sarilumab is a fully human monoclonal antibody that targets the interleukin‑6 (IL‑6) receptor (both membrane‑bound and soluble forms). By blocking IL‑6 from binding to its receptor, sarilumab inhibits the IL-6 mediated inflammatory signaling pathway. This reduces inflammation, immune‑mediated damage, and other symptoms associated with autoimmune inflammatory diseases such as rheumatoid arthritis and polymyalgia rheumatica.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

📘 Sourcing Guide

Sarilumab — third party manufacturing & bulk supply

Sarilumab is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.
Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.
Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

What to include when you enquire

  • Destination market — determines which manufacturers hold the right site-level approvals
  • First order quantity and estimated annual volume
  • Whether you need a registration dossier or the product is already registered
  • Packaging, labelling and language requirements
  • Incoterms and required shelf life

Manufacturers of Sarilumab listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.

Request a quote for Sarilumab →
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing

Frequently Asked Questions

Sarilumab is used to treat moderate to severe rheumatoid arthritis in adults who have not responded adequately to other disease-modifying antirheumatic drugs (DMARDs). It works as an interleukin-6 (IL-6) receptor antagonist, reducing inflammation and slowing joint damage.

Sarilumab is made from a human monoclonal antibody that specifically targets and blocks the IL-6 receptor, preventing the inflammatory effects of IL-6.

The trade name is Kevzara.

Kevzara is manufactured by Regeneron Pharmaceuticals in collaboration with Sanofi.

The generic name is sarilumab.

The primary brand name is Kevzara.

It is manufactured in approved biopharmaceutical facilities in the USA and Europe.

Related Products

Etrasimod Arginine

Strength:
2 mg, 4 mg, 6 mg

Form: Tablets

Reference Brands: Velsipity (USA)

View Details
Avacopan

Strength:
10 mg

Form: Capsules

Reference Brands: Tavneos (USA/EU)

View Details
Fostamatinib Disodium

Strength:
100 mg, 150 mg

Form: Tablets

Reference Brands: Tavalisse (USA)

View Details
Deucravacitinib

Strength:
6 mg

Form: Tablet

Reference Brands: Sotyktu (USA/EU)

View Details
Enquire Now

Quick Response Guaranteed | Verified Suppliers

Subscribe to Our Newsletter

Stay updated on pharma trends and sourcing opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.